Biophytis Temporarily Suspends Share Trading Due to Financial Report Delay

The latest update is out from Biophytis ( (BPTSY) ).

On June 19, 2025, Biophytis announced the temporary suspension of its share trading on Euronext Growth Paris due to the non-publication of its annual financial report for the fiscal year ended December 31, 2024. The suspension began on June 17, 2025, and trading is expected to resume after the report’s publication, anticipated by the end of June 2025. This development may impact stakeholders by temporarily affecting the liquidity and market perception of Biophytis’s shares.

The most recent analyst rating on (BPTSY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.

Spark’s Take on BPTSY Stock

According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.

Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.

To see Spark’s full report on BPTSY stock, click here.

More about Biophytis

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101, is being developed for muscular diseases such as sarcopenia and metabolic disorders like obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis’s ordinary shares are listed on Euronext Growth Paris and its ADS are listed on the OTC market.

Average Trading Volume: 25

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.36M

For detailed information about BPTSY stock, go to TipRanks’ Stock Analysis page.